Search Results 581-590 of 17392 for alopecia

  1. A Study to Assess the Effectiveness, Safety, and Drug/Body Interactions of Rovalpituzumab for Third-Line and Later Treatment of Patients with Small Cell Lung Cancer that has Returned or is Resistant to Treatment - Mayo Clinic

    ... alopecia) prior to initiation of study drug administration; Adequate hematologic and organ function as confirmed by laboratory values; Last dose of any prior ...

  2. Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations - Mayo Clinic

    therapy/procedure excluding alopecia and oxaliplatin induced neurotoxicity =< grade 2 - Albumin levels < 2.5 g/dl - Any of the following because this study ...

  3. A Study to Evaluate Daratumumab/rHuPh20 +/- Lenalidomide as Post-ASCT Maintenance for Multiple Myeloma with Minimal Residual Disease (MRD) to Direct Therapy Duration - Mayo Clinic

    All ASCT-related toxicities must have recovered to ≤ Grade 1 (except for alopecia, fatigue and amenorrhea) prior to first randomization. Mucositis and ...

  4. A Study of STX-0712 in Patients with Advanced Hematologic Malignancies - Mayo Clinic

    ... alopecia, nausea, and fatigue); Clinically significant cardiovascular disease (e.g., uncontrolled or any New York Heart Association class 3 or 4 congestive ...

  5. A Study of Mogamulizumab Combined with Nivolumab in Patients who have Locally Advanced or Metastatic Solid Tumors - Mayo Clinic

    Subject with vitiligo, alopecia, type I diabetes mellitus, and endocrine deficiencies including hypothyroidism managed with replacement hormones including ...

  6. Treatment

    Ependymoma treatment options include: Surgery. Brain surgeons, called neurosurgeons, work to remove as much of the ependymoma as possible.

  7. Mayo Clinic

    Fuel groundbreaking medical research! ... Your donation powers the future of medicine and helps save lives. Give Today.

  8. Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors - Mayo Clinic

    ... alopecia prior to C1D1; Age eighteen years or older; ECOG performance status 0-2, inclusive; Anticipated life expectancy of at least 12 weeks; Adequate bone ...

  9. A Study to Evaluate Trabectedin with Olaparib in Advanced Unresectable or Metastatic Sarcoma - Mayo Clinic

    Persistent toxicities (>Common Terminology Criteria for Adverse Event (CTCAE) grade 2) caused by previous cancer therapy, excluding alopecia. Patients with ...

  10. Chemotherapy Combined With Immunotherapy vs Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial - Mayo Clinic

    following exceptions, which are allowed: alopecia, vitiligo, rheumatoid arthritis, psoriasis/psoriatic arthritis, Hashimoto's thyroiditis, lupus ...